We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toThe-Impact-of-Cell-and-Gene-Therapy-on-the-Payer-System

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.

The Impact of Cell and Gene Therapy on the Payer System

    Session Chair(s)
      Marianne  Hamilton Lopez, PhD, MPA

      Marianne Hamilton Lopez, PhD, MPA

      • Research Director, Value-Based Payment Reform
      • Duke-Margolis Center For Health Policy, United States
    New therapeutic approaches are emerging, including gene therapies, cell therapies, gene editing technologies, and other tissue engineering therapies, that hold the promise of producing long-term and durable responses to serious conditions. Despite their great potential, a key question is how these therapies will impact the payer and reimbursement system due to their potentially high up-front costs within the traditional fee-for-service payment model. This session will focus on the need for a combined stakeholder approach to understand the pipeline of future therapies, to achieve partnerships across sectors, to explore how gene and cell therapies might impact the current payer and reimbursement system, and to address both access and affordability. The session will also present a paper, developed by the Duke-Margolis Value-Based Payment Consortium that considers potential benefits and challenges of proposed value-based payment approaches that have the potential to align payers, manufacturers, and providers towards greater value.
    Learning Objective : In this presentation participants should expect to garner a basic understanding of Cell and Gene Therapies and the difference from small and large molecule therapeutics. Participants will also decipher how those differences impact models for reimbursement and payment. Further, participants will evaluate the influence partnerships will have in developing this payer system.
      Dan  Tierno, MA, MBA

      Cell and Gene Therapy Development and the Impact on the Payer System

      Dan Tierno, MA, MBA

      • Strategic Implementation Manager
      • Bayer, United States